Aaron Cowley | CSO
ReciBioPharm

Dr. Aaron Cowley is the Chief Scientific Officer (CSO) at ReciBioPharm (2019 to present), a leading Contract Development and Manufacturing Organization (CDMO) focused on Advanced Therapy Medicinal Products (ATMP), including but not limited to Live Biotherapeutic Products (LBPs), xRNA, pDNA and oncolytic viruses.  Prior to joining Arranta Bio, Aaron was the co-founder and the Chief Technical Officer (CTO) of Captozyme, which served the microbiome CDMO market since 2009 and merged with Arranta Bio in November 2019.  Prior to founding Captozyme, Aaron was a Scientist II/Pre-clinical Manager at OxThera Inc (Alachua, FL) from 2006-2009, where he was engaged in the development of therapeutic enzymes and live biotherapeutic products (LBP). 
He is a renowned member of the biotech community which is highlighted by Aaron being the recipient of the prestigious Ruth L. Kirschstein National Research Service Award for his post-doctoral work at the University of Georgia and having been the recipient of more than six grants totaling nearly $88 million from the NIH and FDA to develop therapeutic enzymes and continuous xRNA manufacturing production lines. 

His further work has resulted in 17 peer-reviewed journal articles and several patent families. 
He holds a Bachelor’s Degree in Biochemistry from Benedictine College, a Ph.D in Inorganic Chemistry from the University of Kansas (focus: enzymology and implications of redox potentiometry has on function), and an MBA from the University of Florida.
He serves on the Oxidien Pharmaceuticals Board and is a founding member.